Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -4.11M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 600
Avg Vol 1,408
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 37%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surg...

Phone: 781 552 4452
Address:
2 Burlington Woods Drive, Suite 100, Burlington, United States
Latest News on BBLGW
Bone Biologics Announces 1-for-6 Reverse Stock Split

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Bone Biologics Announces 1-for-6 Reverse Stock Split

BBLG


Bone Biologics Reports Progress With NB1 Clinical Program

Mar 1, 2024, 8:00 AM EST - 2 years ago

Bone Biologics Reports Progress With NB1 Clinical Program

BBLG


Bone Biologics Announces 1-for-8 Reverse Stock Split

Dec 18, 2023, 8:00 AM EST - 2 years ago

Bone Biologics Announces 1-for-8 Reverse Stock Split

BBLG


Bone Biologics Effects 1-for-30 Reverse Stock Split

Jun 6, 2023, 1:00 PM EDT - 3 years ago

Bone Biologics Effects 1-for-30 Reverse Stock Split

BBLG


Bone Biologics CEO Issues Letter to Stockholders

Oct 25, 2022, 8:00 AM EDT - 3 years ago

Bone Biologics CEO Issues Letter to Stockholders

BBLG